TY - JOUR
T1 - TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
AU - Alzheimer's Disease Neuroimaging Initiative (ADNI)
AU - Hong, Shengjun
AU - Dobricic, Valerija
AU - Ohlei, Olena
AU - Bos, Isabelle
AU - Vos, Stephanie J.B.
AU - Prokopenko, Dmitry
AU - Tijms, Betty M.
AU - Andreasson, Ulf
AU - Blennow, Kaj
AU - Vandenberghe, Rik
AU - Gabel, Silvy
AU - Scheltens, Philip
AU - Teunissen, Charlotte E.
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni
AU - Blin, Olivier
AU - Richardson, Jill C.
AU - Bordet, Regis
AU - Lleó, Alberto
AU - Alcolea, Daniel
AU - Popp, Julius
AU - Clark, Christopher
AU - Peyratout, Gwendoline
AU - Martinez-Lage, Pablo
AU - Tainta, Mikel
AU - Dobson, Richard J.B.
AU - Legido-Quigley, Cristina
AU - Sleegers, Kristel
AU - Van Broeckhoven, Christine
AU - Tanzi, Rudolph E.
AU - ten Kate, Mara
AU - Wittig, Michael
AU - Franke, Andre
AU - Lill, Christina M.
AU - Barkhof, Frederik
AU - Lovestone, Simon
AU - Streffer, Johannes
AU - Zetterberg, Henrik
AU - Visser, Pieter Jelle
AU - Bertram, Lars
N1 - Publisher Copyright:
© 2021 the Alzheimer's Association
PY - 2021
Y1 - 2021
N2 - Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. Methods: We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses. GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates. Results: We identify novel genome-wide significant associations between DNA variants in TMEM106B and CSF levels of NfL, and between CPOX and YKL-40. We confirm previous work suggesting that YKL-40 levels are associated with DNA variants in CHI3L1. Discussion: Our study provides important new insights into the genetic architecture underlying interindividual variation in three AD-related CSF biomarkers. In particular, our data shed light on the sequence of events regarding the initiation and progression of neuropathological processes relevant in AD.
AB - Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. Methods: We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses. GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates. Results: We identify novel genome-wide significant associations between DNA variants in TMEM106B and CSF levels of NfL, and between CPOX and YKL-40. We confirm previous work suggesting that YKL-40 levels are associated with DNA variants in CHI3L1. Discussion: Our study provides important new insights into the genetic architecture underlying interindividual variation in three AD-related CSF biomarkers. In particular, our data shed light on the sequence of events regarding the initiation and progression of neuropathological processes relevant in AD.
UR - http://www.scopus.com/inward/record.url?scp=85105851942&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ca584a14-532b-3e8c-a8d8-5cb116bfe378/
U2 - 10.1002/alz.12330
DO - 10.1002/alz.12330
M3 - Journal articles
AN - SCOPUS:85105851942
SN - 1552-5260
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -